Cancer Immunotherapy

Breakthroughs in Immunotherapy
Download the e-book for the latest recommendations from leaders in immunotherapy research and their insights into exciting new developments.
Download e-book

Cancer immunotherapy focuses on harnessing and enhancing the innate powers of the immune system to fight cancer. Cell-based therapies typically involve collecting cancer patient immune cells, engineering them to recognize and kill cancer cells, growing large numbers of these engineered cells, and reintroducing them into the same patient.

Immune cell-mediated tumor cell killing can involve the components of both the innate and adaptive immune systems, including natural killer (NK) cells, cytotoxic T cells (MHC-dependent), antibodies secreted by B lymphocytes, engineered antibodies such as bispecific antibodies and bispecific T cell engagers (BiTEs), and genetically engineered T cells targeting specific tumor antigens (e.g., CAR-T, MHC-independent)

Is your current in vitro assay truly predictive of in vivo outcomes?

In addition to being robust and simple, the ideal immune cell killing assay closely mimics activity in vivo. To gain a more complete view of cancer cell killing, the xCELLigence® Real Time Cell Analysis (RTCA) technology captures dynamic cell behavior that can be missed by labor-intensive endpoint methods.

How is xCELLigence RTCA used for killing assays?

The xCELLigence® Real-Time Cell Analysis (RTCA) instrument monitors cell killing in real time. Simply add target and immune effector cells to the patented microtiter plates (E-Plates®), load the instrument, and start reading.

The biosensors embedded in the bottom of each well allow for the automated kinetic measurement of changes in cell number, cell size, and cell-substrate attachment quality.

Target cell death can be measured continuously and automatically, from hours to days, without the use of labels.

Watch the video to learn more.


Reap the benefits of game-changing predictivity with xCELLigence® Real-Time Cell Analysis (RTCA) instruments:

      • Label-Free: No 51Cr, no luciferase, no dyes…NO PROBLEM
      • Astonishingly Simple Workflow: Plate target cells, add effector cells, and start reading
        • Read an entire 96-well plate in 15 seconds
        • Run up to 6 plates independently, with no scheduling conflicts
        • Monitor target cell killing continuously from seconds to days
      • Exquisite Sensitivity: Monitor target cell killing at low, physiologically relevant effector:target ratios
      • Diverse Effector Cells and Molecules: TIL, NK, CART, TCR, checkpoint inhibitors, BiTEs, etc.
      • Quantitative, Real-Time Kinetics: Highly accurate and highly reproducible 
Explore Functional Potency Assays for Cancer Immunotherapy Research
Topics include Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), BiTEs, Bispecific Antibodies, Checkpoint Inhibitors, CAR-T Cells and moreDownload Cancer Immunotherapy Handbook
Simple and High Throughput Workflow

The xCELLigence® Real-Time Cell Analysis (RTCA) instruments utilize patented microtiter plates (E-Plates®) which contain gold biosensors embedded in the bottom of each well. These biosensors continuously and non-invasively monitor changes in cell number, cell size, and cell-substrate attachment quality.


More Accurate & Reproducible Cytolytic Data with xCELLigence RTCA Software Pro
 xCELLigence RTCA Software Pro is an integrated software package that includes a powerful immunotherapy module for running and analyzing real time cell analysis data.

Real time effector cytolysis can be consistently calculated at low, physiologically relevant effector to target ratios.


IMT Handbook

Video – Kinetics of tumor cell killing by tumor-infiltrating lymphocytes

Dr. Cara Haymaker from MD Anderson Cancer Center explores the impact of TIL modification on their ability to kill HLA-matched or autologous tumor cells.

Watch on Demand
Test Alt

Video – Unbiased Functional Identification and Therapeutic Targeting of Tumor Neoantigens

Dr. Stephen Schoenberger from the La Jolla Institute of Immunology discusses his lab’s latest developments in tumor neoantigen targeting.

Watch on Demand
Test Alt

Video – Virus Specific T cells as platform for Solid Tumor Immunotherapy

Dr. John Connolly from Tessa Therapeutics explores predictive biomarkers and discusses virus specific T cell therapies for treatment of solid tumors.

Watch on Demand

Featured xCELLigence RTCA systems for immune cell killing assays:

Dual PurposeSingle PlateMulti PlateHigh Throughput
3×16 wells1×96 wells6×96 wellsUp to 4×384 wells


Cancer Immunotherapy Supporting Information: